CCM
ACAD icon

Cupps Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Cupps Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-41,611
Closed -$1.35M – 178
2016
Q2 		$1.35M Sell
41,611
-83,242
-67% -$2.79M 0.35% 105
2016
Q1 		$3.49M Buy
124,853
+104,238
+506% +$2.27M 0.67% 61
2015
Q4 		$734K Buy
+20,615
New +$726K 0.1% 122
2015
Q2 		– Sell
-153,717
Closed -$5.01M – 188
2015
Q1 		$5.01M Sell
153,717
-118,633
-44% -$4.08M 0.45% 81
2014
Q4 		$8.65M Sell
272,350
-48,471
-15% -$1.37M 0.77% 45
2014
Q3 		$7.94M Sell
320,821
-99,590
-24% -$2.33M 0.74% 49
2014
Q2 		$9.5M Sell
420,411
-3,621
-0.9% -$75.6K 0.77% 49
2014
Q1 		$10.3M Sell
424,032
-419,819
-50% -$10.6M 0.79% 44
2013
Q4 		$21.1M Sell
843,851
-76,166
-8% -$1.8M 1.43% 17
2013
Q3 		$25.3M Sell
920,017
-24,913
-3% -$521K 1.64% 15
2013
Q2 		$17.1M Buy
+944,930
New +$13M 1.37% 23

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Cupps Capital Management's ACAD Position: Q3 2016 in Review

Cupps Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q3 2016, closing a stake of 41,611 shares — an estimated $1.35M sold.

Cupps Capital Management first reported a position in ACAD in Q2 2013 and held it in 11 quarters. The position peaked at $25.3M in Q3 2013. 234 funds tracked by Wall St. Rank hold ACAD as of Q3 2016.

  • Cupps Capital Management reported no remaining Acadia Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Cupps Capital Management sold 41,611 Acadia Pharmaceuticals shares in Q3 2016, an estimated $1.35M.
  • Cupps Capital Management first reported a position in Acadia Pharmaceuticals in Q2 2013 and held it in 11 quarters.
  • Cupps Capital Management's Acadia Pharmaceuticals position peaked at $25.3M in Q3 2013.
  • 234 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2016.

Based on Cupps Capital Management's 13F filing for Q3 2016, filed 11 Oct 2016.